Results 111 to 120 of about 3,975 (165)

Treatment-Emergent Bictegravir Resistance in a Treatment-Naive Individual With HIV Infection: A Case Report. [PDF]

Cureus
Dubson I, Gaur A, Jose J, Andrews C, Gaballa A, McFarlane SI.   +5 more
europepmc   +1 more source

HIV-Associated Diffuse Large B-Cell Lymphoma Treated With Outpatient Pola-R-CHP Without Antiretroviral Therapy Modification: A Case Report. [PDF]

Case Rep Infect Dis
Ikoma Y, Ishihara M, Sugiyama H, Okamoto D, Hayase N, Yamaguchi K, Matsumoto T, Tetsuka N, Nakamura N, Nakamura H, Kanemura N, Shimizu M, Tsurumi H.   +12 more
europepmc   +1 more source

Longitudinal Clinical and Molecular Characterization of a Single Pediatric Case of Vertically Acquired HIV-1 Subtype C with Baseline Resistance to Protease Inhibitors. [PDF]

Microorganisms
Zaher KA, El-Daly MM, Zaki EA, Alhazmi MM, Abdulhaq A, El-Kafrawy SA, Azhar EI.   +6 more
europepmc   +1 more source

VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment. [PDF]

Open Forum Infect Dis
Ghosn J, Pulido F, Lopardo GD, Olczak A, Ripamonti D, Martin C, Paredes Ceballos O, Stocker H, Mendez Vazquez MJ, Gatanaga H, Metallidis S, Elbirt D, Whitlock G, Mateo González JI, Mohammed P, Wang K, Grove R, Wang R, Jewell A, Sutton K, Elliot E, Moodley R, Borsi R, Jones B, Kisare M, Budnik P, van Wyk J, VOGUE Study Group, VOGUE Study Group .   +28 more
europepmc   +1 more source

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort. [PDF]

Rev Esp Quimioter
Cecchini D, Brizuela M, Copertari G, Bacelar B, Lamaizon C, Roel M, Bottaro E, Cassetti I.   +7 more
europepmc   +1 more source

Bictegravir concentrations in breastmilk of healthy, lactating women without HIV. [PDF]

J Antimicrob Chemother
van der Wekken-Pas LC, van Leeuwen E, van Ewijk-Beneken Kolmer EWJ, Burger DM, Colbers AC.   +4 more
europepmc   +1 more source

Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials. [PDF]

Open Forum Infect Dis
Post FA, Wohl D, Liegeon G, Brar I, Hagins D, Yazdanpanah Y, Avihingsanon A, Liu H, Aizen K, Hindman JT, Gupta S.   +10 more
europepmc   +1 more source

Bictegravir/Tenofovir Alafenamide/Emtricitabine in Real-Life: A Multi-Year Experience. [PDF]

J Clin Med
Gidari A, Baranello E, Pallotto C, Morosi S, Papalini C, Gamboni G, Malincarne L, Rosignoli D, Benvenuto MC, Gonnelli G, Ucciferri C, Socio GV.   +11 more
europepmc   +1 more source

Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023. [PDF]

Clin Infect Dis
Le JN, Zhu W, Huang YA, Wei W, O'Shea J, Mann LM, Tanner MR, Kourtis AP, Hoover KW.   +8 more
europepmc   +1 more source

Post-marketing safety profile of bictegravir/emtricitabine/tenofovir alafenamide: a FAERS pharmacovigilance study with EudraVigilance validation and mechanistic investigation of pancreatitis. [PDF]

Virol J
Xie Y, Luo Y, Chen Y, Shi G, He Y, Liu X, Cui Z, Zou F, Zhu C.   +8 more
europepmc   +1 more source